Bone Cancer

Categories: Bone diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Bone Cancer

MalaCards integrated aliases for Bone Cancer:

Name: Bone Cancer 12 42 15
Malignant Bone Neoplasm 12 17 70
Bone Carcinoma 12 15 70
Bone Neoplasms 73 44 70
Bone Neoplasm 12 17
Malignant Neoplasm of Bone 12
Malignant Osseous Tumor 12
Malignant Bone Tumour 12
Osteosarcoma of Bone 70
Osteogenic Neoplasm 70
Ca - Bone Cancer 12
Neoplasm of Bone 12
Osseous Tumor 12
Bone Tumour 12


External Ids:

Disease Ontology 12 DOID:184 DOID:2762
MeSH 44 D001859
NCIt 50 C36082 C9343
SNOMED-CT 67 126537000 269568000
UMLS 70 C0005967 C0279530 C0585442 more

Summaries for Bone Cancer

MedlinePlus : 42 Cancer that starts in a bone is uncommon. Cancer that has spread to the bone from another part of the body is more common. There are three types of bone cancer: Osteosarcoma - occurs most often between ages 10 and 19. It is more common in the knee and upper arm. Chondrosarcoma - starts in cartilage, usually after age 40 Ewing's sarcoma - occurs most often in children and teens under 19. It is more common in boys than girls. The most common symptom of bone cancer is pain. Other symptoms vary, depending on the location and size of the cancer. Surgery is often the main treatment for bone cancer. Other treatments may include amputation, chemotherapy, and radiation therapy. Because bone cancer can come back after treatment, regular follow-up visits are important. NIH: National Cancer Institute

MalaCards based summary : Bone Cancer, also known as malignant bone neoplasm, is related to bone marrow cancer and osteogenic sarcoma, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Bone Cancer is TNFSF11 (TNF Superfamily Member 11), and among its related pathways/superpathways are GPCR Pathway and ERK Signaling. The drugs Denosumab and Pregabalin have been mentioned in the context of this disorder. Affiliated tissues include bone, prostate and spinal cord, and related phenotypes are behavior/neurological and growth/size/body region

Disease Ontology : 12 A connective tissue cancer that is located in bone and is characterized by uncontrolled cellular proliferation that destroys normal bone tissue.

Wikipedia : 73 A bone tumor is a neoplastic growth of tissue in bone. Abnormal growths found in the bone can be either... more...

Related Diseases for Bone Cancer

Diseases in the Bone Cancer family:

Primary Bone Cancer

Diseases related to Bone Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 525)
# Related Disease Score Top Affiliating Genes
1 bone marrow cancer 32.8 TP53 TNFSF11 SERPINA3 MIR9-1 IL6 EGFR
2 osteogenic sarcoma 32.6 TP53 TNFSF11 MMP9 IL6 CYCS CDKN2A
3 bone squamous cell carcinoma 32.2 TP53 MMP9 EGFR CDKN2A CCND1
4 bone sarcoma 32.2 TP53 SERPINA3 MTAP MIR9-1 IL6
5 li-fraumeni syndrome 32.1 TP53 ESR1 EGFR CDKN2A
6 bone disease 31.2 TNFSF11 MMP9 IL6 ESR1 COL1A1 CCL2
7 bone resorption disease 31.1 TNFSF11 SERPINA3 IL6 ESR1 COL1A1 BMP2
8 ewing sarcoma 31.1 TP53 MMP9 IL6 EGFR CDKN2A CCND1
9 pain agnosia 31.1 TRPV1 PDYN IL6
10 keratocystic odontogenic tumor 30.9 TP53 TNFSF11 MMP9 CCND1
11 sarcoma 30.9 TP53 MTAP IL6 CYCS CCND1
12 chordoma 30.8 TP53 SERPINA3 MTAP EGFR CDKN2A
13 osteomyelitis 30.7 TNFSF11 IL6 CCL2 BMP2
14 myeloma, multiple 30.6 TP53 TNFSF11 MIR9-1 IL6 EGFR CYCS
15 neurofibroma 30.6 TP53 EGFR CDKN2A
16 fasciitis 30.5 TP53 IL6 ESR1
17 bone inflammation disease 30.5 TNFSF11 SERPINA3 MMP9 IL6 CCL2
18 pigmented villonodular synovitis 30.5 TP53 TNFSF11 SERPINA3 MMP9
19 connective tissue benign neoplasm 30.4 TP53 TNFSF11 SERPINA3
20 dermatofibrosarcoma protuberans 30.4 TP53 SERPINA3 COL1A1 CDKN2A
21 osteonecrosis 30.4 TNFSF11 ESR1 BMP2
22 myxofibrosarcoma 30.4 TP53 SERPINA3 MTAP
23 mammary paget's disease 30.4 TNFSF11 ESR1 EGFR
24 hemangioma 30.4 TP53 MMP9 IL6 CYCS
25 adenoid cystic carcinoma 30.4 TP53 SERPINA3 MMP9 EGFR CDKN2A CCND1
26 burkitt lymphoma 30.4 TP53 IL6 CYCS CDKN2A BMI1
27 meningioma, familial 30.4 TP53 SERPINA3 ESR1 EGFR CDKN2A
28 estrogen-receptor positive breast cancer 30.3 TP53 ESR1 EGFR CCND1
29 benign giant cell tumor 30.3 TNFSF11 SERPINA3 MMP9
30 prostate cancer 30.3 TP53 TNFSF11 SERPINA3 MMP9 MAPK7 IL6
31 ameloblastoma 30.3 TP53 TNFSF11 SERPINA3 MMP9
32 adenosquamous carcinoma 30.3 TP53 SERPINA3 EGFR CDKN2A
33 colon adenocarcinoma 30.3 TP53 ESR1 EGFR CYCS CCND1
34 pheochromocytoma 30.3 PDYN IL6 ESR1 CYCS CDKN2A CCND1
35 oral cancer 30.3 TP53 MMP9 EGFR CDKN2A CCND1
36 mantle cell lymphoma 30.3 TP53 IL6 CDKN2A CCND1 BMI1
37 neuroma 30.3 TRPV1 SERPINA3 IL6
38 malignant fibrous histiocytoma 30.3 TP53 SERPINA3 MTAP
39 connective tissue cancer 30.3 TP53 SERPINA3 MIR9-1 EGFR CDKN2A
40 breast adenocarcinoma 30.3 TP53 TNFSF11 SERPINA3 MMP9 ESR1 EGFR
41 osteoporosis 30.3 TRPV1 TP53 TNFSF11 MMP9 IL6 ESR1
42 chronic kidney disease 30.2 TNFSF11 SERPINA3 MMP9 IL6 CCL2
43 carcinosarcoma 30.2 TP53 EGFR CDKN2A
44 skin carcinoma 30.2 TP53 MMP9 MIR9-1 IL6 ESR1 EGFR
45 esophageal cancer 30.1 TP53 MMP9 MIR9-1 IL6 EGFR CYCS
46 peripheral nervous system disease 30.1 TRPV1 TP53 SERPINA3 MMP9 MIR9-1 IL6
47 intracranial meningioma 29.8 ESR1 CDKN2A
48 chest wall bone cancer 11.2
49 primary bone cancer 11.2
50 maxillary cancer 11.0

Graphical network of the top 20 diseases related to Bone Cancer:

Diseases related to Bone Cancer

Symptoms & Phenotypes for Bone Cancer

UMLS symptoms related to Bone Cancer:

back pain; sciatica; muscle cramp

MGI Mouse Phenotypes related to Bone Cancer:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.45 ATF3 CCND1 CDKN2A COL1A1 CYCS ESR1
2 growth/size/body region MP:0005378 10.45 ATF3 BMP2 CCND1 CDKN2A COL1A1 CYCS
3 cardiovascular system MP:0005385 10.41 BMP2 CCND1 CDKN2A COL1A1 CYCS EGFR
4 homeostasis/metabolism MP:0005376 10.4 ATF3 BMP2 CCND1 CDKN2A COL1A1 EGFR
5 immune system MP:0005387 10.39 ATF3 BMP2 CCL2 CCND1 CDKN2A COL1A1
6 cellular MP:0005384 10.37 BMP2 CCND1 CDKN2A COL1A1 CYCS EGFR
7 hematopoietic system MP:0005397 10.35 ATF3 BMP2 CCND1 CDKN2A COL1A1 CYCS
8 integument MP:0010771 10.34 ATF3 CCND1 CDKN2A COL1A1 EGFR ESR1
9 digestive/alimentary MP:0005381 10.32 BMP2 CCND1 CDKN2A COL1A1 EGFR ESR1
10 endocrine/exocrine gland MP:0005379 10.26 ATF3 CCND1 CDKN2A COL1A1 CYCS EGFR
11 embryo MP:0005380 10.22 BMP2 CDKN2A COL1A1 CYCS EGFR ESR1
12 adipose tissue MP:0005375 10.21 ATF3 COL1A1 EGFR ESR1 IL6 PDYN
13 nervous system MP:0003631 10.21 ATF3 BMP2 CCND1 CDKN2A COL1A1 CYCS
14 craniofacial MP:0005382 10.19 BMP2 CCND1 COL1A1 CYCS EGFR MAPK7
15 neoplasm MP:0002006 10.14 ATF3 CCND1 CDKN2A COL1A1 EGFR ESR1
16 muscle MP:0005369 10.09 CDKN2A COL1A1 EGFR ESR1 IL6 MAPK7
17 liver/biliary system MP:0005370 10.06 CDKN2A COL1A1 EGFR ESR1 IL6 MTAP
18 limbs/digits/tail MP:0005371 10.02 BMP2 COL1A1 EGFR ESR1 MMP9 TNFSF11
19 no phenotypic analysis MP:0003012 9.97 ATF3 CDKN2A COL1A1 EGFR ESR1 PDYN
20 renal/urinary system MP:0005367 9.86 COL1A1 EGFR ESR1 IL6 MAPK7 MMP9
21 reproductive system MP:0005389 9.85 BMP2 CCND1 CDKN2A COL1A1 EGFR ESR1
22 respiratory system MP:0005388 9.7 ATF3 CCND1 CDKN2A COL1A1 EGFR ESR1
23 skeleton MP:0005390 9.4 BMP2 CCND1 CDKN2A COL1A1 CYCS EGFR

Drugs & Therapeutics for Bone Cancer

Drugs for Bone Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 168)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Denosumab Approved Phase 4 615258-40-7
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
3 Immunologic Factors Phase 4
4 Immunoglobulins Phase 4
5 Antibodies Phase 4
6 Antibodies, Monoclonal Phase 4
7 Immunoglobulins, Intravenous Phase 4
8 Immunoglobulin G Phase 4
9 Analgesics Phase 4
10 Hormones Phase 4
11 Psychotropic Drugs Phase 4
12 Anticonvulsants Phase 4
13 Anti-Anxiety Agents Phase 4
14 calcium channel blockers Phase 4
15 Calcium, Dietary Phase 4
Calcium Nutraceutical Phase 4 7440-70-2 271
sodium fluoride Approved Phase 3 7681-49-4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
Zoledronic Acid Approved Phase 3 118072-93-8 68740
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
Cefazolin Approved Phase 3 25953-19-9 33255 656510
Ethanol Approved Phase 3 64-17-5 702
Phenol Approved, Experimental Phase 3 108-95-2 996
Captopril Approved Phase 3 62571-86-2 44093
Irinotecan Approved, Investigational Phase 3 100286-90-6, 97682-44-5 60838
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
Daunorubicin Approved Phase 3 20830-81-3 30323
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
30 Grape Approved Phase 3
31 Cranberry Approved, Investigational Phase 3
Tranexamic Acid Approved Phase 3 1197-18-8 5526
Etanercept Approved, Investigational Phase 2, Phase 3 185243-69-0
Molybdenum Approved Phase 3 7439-98-7 185498
Camptothecin Experimental Phase 3 7689-03-4
36 Protective Agents Phase 3
37 Fluorides Phase 3
38 Listerine Phase 3
39 Analgesics, Opioid Phase 3
40 Narcotics Phase 3
41 Anesthetics, General Phase 3
42 Anesthetics, Intravenous Phase 3
43 Hormone Antagonists Phase 3
44 Antiemetics Phase 3
45 Antineoplastic Agents, Hormonal Phase 3
46 glucocorticoids Phase 3
47 Cephalosporins Phase 3
48 Antitubercular Agents Phase 3
49 BB 1101 Phase 3
50 Mitogens Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 219)
# Name Status NCT ID Phase Drugs
1 A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety Completed NCT00434447 Phase 4 Zoledronic acid
2 Open-Label Study to Establish the Short Term Efficacy of Intravenous Loading-Doses of Bondronat 6 mg in Patients With Breast Cancer and Skeletal Metastases Experiencing Moderate to Severe Pain, Within 7 Days After Initiation of Treatment Completed NCT02553707 Phase 4 Ibandronate
3 An Open Label Study of the Efficacy, Safety, and Pharmacoeconomics of Oral Ibandronate (Bondronat 50 mg) in Treatment of Metastatic Bone Disease Completed NCT02564107 Phase 4 Ibandronate
4 A Prospective, Single-arm Multicenter Study to Evaluate Effect of Intravenous Zoledronic Acid on Bone Metabolism Given Over 4 Months in Patients With Prostate Cancer or Breast Cancer and Bone Metastasis Completed NCT00334139 Phase 4 Zoledronic Acid
5 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4 zoledronic acid
6 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4 Zoledronic acid
7 An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures Completed NCT00211211 Phase 4
8 A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid and Circulating Tumor Cell Measurements in Patients With HER2-negative Metastatic Breast Cancer Without Bone Metastasis Completed NCT01129336 Phase 4 Zoledronic acid;Standard Therapy
9 A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
10 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
11 Bioactive Glass Granules as Bone Graft Substitute in Filling Material of Bone Defects Completed NCT01304121 Phase 4
12 A Phase 4 Long-term Follow-up Study to Define the Safety Profile of Radium-223 Dichloride Recruiting NCT02312960 Phase 4
13 Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Active, not recruiting NCT03301857 Phase 4 Denosumab (Cohort A)
14 Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer: A Non-inferiority, Randomized, Open, Parallel and Controlled Prospective Clinical Study Not yet recruiting NCT02480634 Phase 4 Zoledronic acid
15 An Open-label, Multi-center, Phase 4 Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone Not yet recruiting NCT04586660 Phase 4 XGEVA®
16 A Randomized Placebo-Controlled Trial Of The Efficacy And Tolerability Of Flexibly Dosed Pregabalin In The Treatment Of Cancer-Induced Bone Pain Terminated NCT00381095 Phase 4 Pregabalin;Placebo
17 Phase 3 Study Evaluating Fentanyl Transmucosal in the Prevention of Pain Induced by Mobilization During Radiotherapy in Patients With Bone Metastasis Unknown status NCT02426697 Phase 3 fentanyl transmucosal;Placebo
18 18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques Unknown status NCT00882609 Phase 3
19 Biological Image Guided Antalgic Stereotactic Body Radiotherapy of Bone Metastases: a Randomized Phase II/III Trial Unknown status NCT01429493 Phase 2, Phase 3
20 Clinical, Pathologic Characteristics and Its Mechansim of Denosumab Treated Giant Cell Tumor of Bone Unknown status NCT03259152 Phase 3 Denosumab
21 Laser Therapy Prevents Mucositis Oral in Patients Undergoing to Chemotherapy for Bone Marrow Transplantation? A Randomized Clinical Trial. Unknown status NCT02020928 Phase 3
22 Randomized, Open Label Study to Evaluate Renal Safety of Intravenous Bondronat 6 mg Infusions Over 15 Minutes Versus 60 Minutes in Patients With Metastatic Bone Disease Due to Breast Cancer Completed NCT02716792 Phase 3 Ibandronate
23 Randomized, Open Label Study to Assess the Efficacy and Safety of the Intravenous and Oral Ibandronic Acid for Improving the Performance Status of Patients With Malignant Bone Disease Secondary to Solid Tumors and Hematological Malignancies Completed NCT02561039 Phase 3 Ibandronate
24 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer Completed NCT00321464 Phase 3 Zoledronic Acid
25 A Randomized Phase III Double-Blind Study of Dexamethasone Versus Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases Completed NCT01248585 Phase 3 Dexamethasone;Placebo
26 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma. Completed NCT00330759 Phase 3 Zoledronic Acid
27 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer Completed NCT00321620 Phase 3 zoledronic acid
28 Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): A Multi-Center International Randomized Controlled Trial Comparing Alternative Antibiotic Regimens in Patients Undergoing Tumor Resections With Endoprosthetic Replacements Completed NCT01479283 Phase 3 24-Hour Prophylactic Cefazolin* Antibiotic Regimen;5-Days Prophylactic Cefazolin* Antibiotic Regimen
29 A Randomized, Double-blind, Multi-centre Study to Evaluate the Fficacy and Safety of Zometa as a Treatment in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma Completed NCT00219258 Phase 3 Zoledronic acid
30 Investigation of Optimal Radiotherapy Regimen and Type of Irradiation in Treatment of Painful Bone Metastasis Completed NCT00610272 Phase 3
31 A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms Completed NCT02163226 Phase 2, Phase 3
32 Dexamethasone for the Prevention of a Pain Flare After Palliative Radiotherapy for Painful Bone Metastases: a Multi-center Double-blind Placebo-controlled Randomized Study Completed NCT01669499 Phase 3 Dexamethasone acetate;Placebo
33 Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer Completed NCT01419717 Phase 3 Denosumab
34 Phase III Study of Palliative Radiotherapy for Bone Metastases Comparing Single to Multiple Fractions. Completed NCT00858741 Phase 3
35 An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab in the Treatment of Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma Completed NCT00950911 Phase 3 amg 162
36 Randomized Phase 2 Study on the Relationship Between Circulating VEGF and Weekly or Every-four-week Zometa in Breast Cancer Patients With Bone Metastases Completed NCT00524849 Phase 2, Phase 3 Zoledronic acid
37 Tranexamic Acid (TXA) to Reduce Volume Of Blood Transfused In Pediatric And Young Adult Cancer Patients Undergoing Limb Salvage Procedure Of A Lower Extremity Recruiting NCT04410042 Phase 3 Tranexamic Acid
38 Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone: A Prospective Randomized Controlled Trial Recruiting NCT03295981 Phase 3 Zoledronic Acid
39 Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia Recruiting NCT03389724 Phase 3 Capoten®
40 A Multi-center, Randomized, Double-blind, Comparative Study to Evaluate the Clinical Efficacy and Safety of QL1206 and Xgeva® in Patients With Bone Metastases From Solid Tumors Recruiting NCT04550949 Phase 3 QL1206;Xgeva
41 Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients With Bone Metastases Recruiting NCT04307914 Phase 3
42 Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Active, not recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Etoposide Phosphate;Ifosfamide;Vincristine;Vincristine Sulfate
43 A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination With Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma Active, not recruiting NCT03495921 Phase 3 Irinotecan;Temozolomide
44 A Multi-center, Randomized, Double-blind, Parallel Controlled Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of Recombinant Human Anti RANKL Monoclonal Antibody Injection (MW032) and Denosumab (Xgeva®) in Subjects With Bone Metastases From Solid Tumors Active, not recruiting NCT04812509 Phase 3 MW032;Xgeva
45 Postoperative Bleeding Prevention in Massive Bone Tumour Resection: a Multicentric, Randomized, Parallel, Controlled Trial to Assess the Efficacy of Tranexamic Acid Versus Evicel® and Usual Haemostasis Terminated NCT02153593 Phase 3 Tranexamic Acid;Fibrin glue
46 A Prospective, Randomized Pilot Study of Enbrel VS Placebo in Patients Receiving Radiation Therapy to Combat Fatigue and Cachexia Terminated NCT00127387 Phase 2, Phase 3 Enbrel
47 A Randomized, Placebo-controlled, Double-blind Study of the Effect of Bondronat Compared With Zoledronic Acid on Pain in Patients With Malignant Bone Disease Experiencing Moderate to Severe Pain Terminated NCT00099203 Phase 3 ibandronate [Bondronat];zoledronic acid
48 A Cross-over Comparison of the Diagnostic Accuracy of Technetium (99mTc) Medronate Injection Prepared With 99mTc Derived From Neutron-activation Produced 99Mo Versus the Current Reference Standard of 99mTc Derived From Fission-produced 99Mo Terminated NCT03002454 Phase 3 99mTc MDP Injection:neutron-bombardment
49 A Randomized, Double-blind Study of the Effect of Bondronat Compared With Zoledronic Acid on Pain in Patients With Malignant Bone Disease Experiencing Moderate to Severe Pain Terminated NCT00099177 Phase 3 ibandronate [Bondronat];zoledronic acid
50 Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions Withdrawn NCT00851162 Phase 2, Phase 3

Search NIH Clinical Center for Bone Cancer

Inferred drug relations via UMLS 70 / NDF-RT 51 :

zoledronic acid

Cochrane evidence based reviews: bone neoplasms

Genetic Tests for Bone Cancer

Anatomical Context for Bone Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Bone Cancer:


MalaCards organs/tissues related to Bone Cancer:

Bone, Prostate, Spinal Cord, Breast, Dorsal Root Ganglion, Brain, Bone Marrow

Publications for Bone Cancer

Articles related to Bone Cancer:

(show top 50) (show all 1714)
# Title Authors PMID Year
Impact of the COVID-19 pandemic on quality of life and emotional wellbeing in patients with bone metastases treated with radiotherapy: a prospective cohort study. 42
33634347 2021
Effect of TIMP2/TIMP3 genes on the risk of osteosarcoma in Zhejiang population. 42
33725949 2021
Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer. 42
33731701 2021
Hsa_circ_0032463 acts as the tumor promoter in osteosarcoma by regulating the miR‑330‑3p/PNN axis. 61
33786605 2021
Magnetic bioactive glasses/Cisplatin loaded-chitosan (CS)-grafted- poly (ε-caprolactone) nanofibers against bone cancer treatment. 61
33593554 2021
Dorsal root ganglia NR2B-mediated Epac1-Piezo2 signaling pathway contributes to mechanical allodynia of bone cancer pain. 61
33692870 2021
Augmented Antitumor Activity for Novel Dual PI3K/BDR4 Inhibitors, SF2523 and SF1126 in Ewing Sarcoma. 61
33480647 2021
The circular RNA circSlc7a11 promotes bone cancer pain pathogenesis in rats by modulating LLC-WRC 256 cell proliferation and apoptosis. 61
33433832 2021
Assessment and management of metastatic bone cancer in emergency departments. 61
33231019 2021
An oligopeptide/aptamer-conjugated dendrimer-based nanocarrier for dual-targeting delivery to bone. 61
33704322 2021
Synthesis and Characterization of Silver-Strontium (Ag-Sr)-Doped Mesoporous Bioactive Glass Nanoparticles. 61
33805013 2021
Imaging of Bone Sarcomas and Soft-Tissue Sarcomas. 61
33772487 2021
Holmium-Containing Bioactive Glasses Dispersed in Poloxamer 407 Hydrogel as a Theragenerative Composite for Bone Cancer Treatment. 61
33802678 2021
The role of Notch ligand Jagged1 in osteosarcoma proliferation, metastasis, and recurrence. 61
33781318 2021
miR-485-3p regulated by MALAT1 inhibits osteosarcoma glycolysis and metastasis by directly suppressing c-MET and AKT3/mTOR signalling. 61
33358903 2021
Circ_0016347 Promotes Osteosarcoma Progression by Regulating miR-1225-3p/KCNH1 Axis. 61
33764794 2021
Adjuvant electrochemotherapy after debulking in canine bone osteosarcoma infiltration. 61
32959401 2021
Role of TRPA1 expressed in bone tissue and the antinociceptive effect of the TRPA1 antagonist repeated administration in a breast cancer pain model. 61
33811892 2021
Co-occurrence of malignant neoplasm and Hyperostosis Frontalis Interna in an Iron Age individual from Münsingen-Rain (Switzerland): A multi-diagnostic study. 61
33176226 2021
The Combination of Amygdalin with Some Anticancer, Antiparasitic, and Antigout Drugs Against MG63, Saos2, SW1353, and FL Cells In Vitro. 61
33733877 2021
Modelling count data with an excess of zero values applied to childhood bone tumour incidence in Iraq. 61
33733648 2021
Protopanaxadiol alleviates neuropathic pain by spinal microglial dynorphin A expression following glucocorticoid receptor activation. 61
33786848 2021
Ultrasound-guided pericapsular nerve group and obturator nerve phenol neurolysis for refractory inpatient hip cancer metastasis pain: a case report. 61
33766686 2021
Design strategies and evolving role of biomaterial assisted treatment of osteosarcoma. 61
33579498 2021
Transformed notochordal cells trigger chronic wounds destabilizing the vertebral column and bone homeostasis. 61
33579726 2021
Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma. 61
33672770 2021
The roles of metastasis-related proteins in the development of giant cell tumor of bone, osteosarcoma and Ewing's sarcoma. 61
33682749 2021
Hierarchically Porous Osteoinductive Poly(hydroxyethyl methacrylate-co-methyl methacrylate) Scaffold with Sustained Doxorubicin Delivery for Consolidated Osteosarcoma Treatment and Bone Defect Repair. 61
33395260 2021
GEM-Based Metabolic Profiling for Human Bone Osteosarcoma under Different Glucose and Glutamine Availability. 61
33540580 2021
Identifying biomolecules and constructing a prognostic risk prediction model for recurrence in osteosarcoma. 61
33376666 2021
Horseradish Peroxidase-Crosslinked Calcium-Containing Silk Fibroin Hydrogels as Artificial Matrices for Bone Cancer Research. 61
33522095 2021
A New Medical Record Proposal to the Prognostic Risk Assessment for MRONJ in Oncologic Patients: "Sapienza Head and Neck Unit" Proposal. 61
33672876 2021
Ubiquitin-specific protease 6 functions as a tumor suppressor in Ewing Sarcoma through immune activation. 61
33558334 2021
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year. 61
33730783 2021
Blockade of spinal dopamine D1/D2 receptor suppresses activation of NMDA receptor through Gαq and Src kinase to attenuate chronic bone cancer pain. 61
33364051 2021
The role of the M1/M2 microglia in the process from cancer pain to morphine tolerance. 61
33220596 2021
Blockade of Spinal EphA4 Reduces Chronic Inflammatory Pain in Mice. 61
33541257 2021
Sol-gel-derived 58S bioactive glass containing holmium aiming brachytherapy applications: A dissolution, bioactivity, and cytotoxicity study. 61
33321639 2021
18F-labeled bisphosphonate as an alternative candidate to the gold standard [18F]sodium fluoride ([18F]NaF) for PET bone imaging. 61
33593263 2021
Electroacupuncture Attenuates Morphine Tolerance in Rats with Bone Cancer Pain by Inhibiting PI3K/Akt/JNK1/2 Signaling Pathway in the Spinal Dorsal Horn. 61
33660537 2021
Bone Marrow Adipocytes: A Link between Obesity and Bone Cancer. 61
33498240 2021
YAP/TAZ inhibition reduces metastatic potential of Ewing sarcoma cells. 61
33419969 2021
Systems Biology Analysis for Ewing Sarcoma. 61
33326111 2021
Systems for local, sustained release of zoledronic acid as a potential treatment for metastatic bone disease. 61
33255000 2021
Physiologic osteoclasts are not sufficient to induce skeletal pain in mice. 61
32955748 2021
Bupivacaine and Lidocaine Induce Apoptosis in Osteosarcoma Tumor Cells. 61
33009230 2021
Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. 61
33408328 2021
Surgical Advances in Osteosarcoma. 61
33494243 2021
Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma. 61
33503424 2021
Unusual presentation of lumbar chordoma on bone scintigraphy in a young patient. 61
33392355 2021

Variations for Bone Cancer

Copy number variations for Bone Cancer from CNVD:

# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 70082 12 58138784 58142025 Amplification TSPAN31 Bone cancer
2 70083 12 58141509 58146230 Amplification CDK4 Bone cancer
3 71134 12 67700000 68661632 Amplification MDM2 Bone cancer

Expression for Bone Cancer

Search GEO for disease gene expression data for Bone Cancer.

Pathways for Bone Cancer

Pathways related to Bone Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
12.82 TP53 IL6 CYCS CCND1 CCL2
Show member pathways
Show member pathways
Show member pathways
Show member pathways
13 12.53 TP53 MMP9 IL6 ESR1 EGFR CYCS
Show member pathways
15 12.34 TP53 IL6 CDKN2A CCND1
Show member pathways
12.33 MMP9 MAPK7 IL6 CCL2
Show member pathways
12.32 TP53 SERPINA3 IL6 CCL2
Show member pathways
Show member pathways
12.29 TP53 IL6 EGFR CCND1 BMP2
Show member pathways
12.28 TP53 EGFR COL1A1 CCL2
21 12.25 TP53 MMP9 IL6 BMI1
22 12.22 TP53 MMP9 ESR1 EGFR COL1A1 CCND1
23 12.13 TP53 IL6 CDKN2A CCND1
24 12.13 TP53 MMP9 IL6 EGFR CCND1
25 12.12 TP53 ESR1 EGFR CCND1
26 12.06 TP53 MMP9 MAPK7 CCL2
27 12.05 TP53 MMP9 MIR9-1 MAPK7 EGFR CDKN2A
28 11.95 TP53 MMP9 IL6 CCND1 CCL2
29 11.94 TP53 EGFR CDKN2A CCND1
30 11.88 IL6 COL1A1 CCND1 CCL2
31 11.79 TP53 MMP9 BMI1
32 11.76 TP53 IL6 COL1A1 CDKN2A BMP2 BMI1
33 11.74 TP53 CYCS CDKN2A
Show member pathways
35 11.69 TP53 CDKN2A BMP2 ATF3
36 11.68 ESR1 EGFR CCND1
37 11.68 MMP9 EGFR CYCS
38 11.67 MMP9 IL6 EGFR
39 11.67 TP53 MMP9 EGFR CDKN2A CCND1
Show member pathways
11.65 MMP9 IL6 CCND1
41 11.65 MMP9 IL6 CCL2
42 11.63 MMP9 EGFR COL1A1
43 11.58 IL6 CCND1 ATF3
44 11.53 TP53 IL6 CCND1
45 11.47 TNFSF11 IL6 COL1A1
46 11.43 TP53 IL6 EGFR CDKN2A CCND1
47 11.39 TNFSF11 COL1A1 CCND1
48 11.31 MMP9 IL6 CCND1 CCL2
49 11.25 TP53 PDYN MMP9 IL6 EGFR CCND1
50 11.01 SERPINA3 CCND1 CCL2

GO Terms for Bone Cancer

Biological processes related to Bone Cancer according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 10.07 TRPV1 TP53 ESR1 CCND1 BMP2 BMI1
2 negative regulation of cell proliferation GO:0008285 9.99 TP53 MIR9-1 IL6 CDKN2A BMP2
3 positive regulation of transcription, DNA-templated GO:0045893 9.98 TP53 IL6 ESR1 EGFR COL1A1 CDKN2A
4 inflammatory response GO:0006954 9.96 TRPV1 SERPINA3 IL6 CCL2 BMP2
5 positive regulation of gene expression GO:0010628 9.95 TP53 TNFSF11 IL6 CDKN2A BMP2 ATF3
6 positive regulation of protein phosphorylation GO:0001934 9.88 MMP9 EGFR CCND1 BMP2
7 positive regulation of apoptotic process GO:0043065 9.85 TRPV1 TP53 MMP9 IL6 CDKN2A BMP2
8 response to estradiol GO:0032355 9.76 ESR1 EGFR COL1A1 CCND1
9 positive regulation of epithelial to mesenchymal transition GO:0010718 9.72 IL6 COL1A1 BMP2
10 monocyte chemotaxis GO:0002548 9.71 TNFSF11 IL6 CCL2
11 liver regeneration GO:0097421 9.67 IL6 EGFR CCND1
12 cytokine-mediated signaling pathway GO:0019221 9.63 TP53 TNFSF11 MMP9 IL6 CCND1 CCL2
13 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.62 TP53 ESR1
14 regulation of neuroinflammatory response GO:0150077 9.62 MMP9 IL6
15 cellular response to growth factor stimulus GO:0071363 9.62 TRPV1 MAPK7 EGFR BMP2
16 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.61 TP53 ESR1
17 mammary gland epithelial cell proliferation GO:0033598 9.61 TNFSF11 CCND1
18 positive regulation of transcription by RNA polymerase II GO:0045944 9.61 TP53 TNFSF11 MAPK7 IL6 ESR1 EGFR
19 mitotic G1 DNA damage checkpoint GO:0031571 9.6 TP53 CCND1
20 tooth eruption GO:0044691 9.58 TNFSF11 COL1A1
21 mammary gland alveolus development GO:0060749 9.58 TNFSF11 ESR1 CCND1
22 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.57 TP53 MAPK7
23 response to UV-A GO:0070141 9.51 EGFR CCND1
24 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.43 TP53 IL6 EGFR
25 ossification GO:0001503 9.02 TNFSF11 MMP9 EGFR COL1A1 BMP2

Molecular functions related to Bone Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.65 TP53 ESR1 EGFR CDKN2A CCND1
2 cytokine activity GO:0005125 9.62 TNFSF11 IL6 CCL2 BMP2
3 identical protein binding GO:0042802 9.23 TRPV1 TP53 TNFSF11 MMP9 ESR1 EGFR
4 MDM2/MDM4 family protein binding GO:0097371 9.16 TP53 CDKN2A
5 nitric-oxide synthase regulator activity GO:0030235 8.96 ESR1 EGFR

Sources for Bone Cancer

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....